AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 5 of 5
The constant demand for more powerful and energy-efficient electronic devices than existing ones is challenging scientists and companies to develop innovative solutions that can address such primary technological needs. Based on a recent scientific discovery made by our team we have developed a technology for superfast and extremely scalable logic and computing circuits with minimal energy losses, which has the potential to become the leading technology in the future world of largescale computing and telecommunication infrastructures.
The proposed technology deals with the development of active SERS (Surface Enhanced Raman Scattering) substrates ad hoc designed for diagnostics of cultural heritage. The substrates are prepared starting from common commercial 'polishing film' sheets (lapping optical fibers) showing an intrinsic roughness (48- 1000 nm) that favors the SERS effect. A pattern of silver or gold nanoparticles are deposited on these films through Pulsed Laser Deposition (PLD).
The software is based on mathematical models able of simulating the time evolution of the different stages of a pest population starting from environmental data collected from weather stations located in an area of interest and information regarding the development stage of the host plant. The models are of two types: phenological, which provides information on the stages population as a function of time and demographic which also allows to know the abundance of each population stage.
This technology is based on an algorithm able to provide the probability of being asthmatic with high accuracy. This probability is based on the evaluation of respiratory function and, specifically, of forced expiratory vital capacity in the first second (FEV1), in resting conditions, and 20 minutes after administration of a bronchodilator drug.